Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond.

ABSTRACT: The therapeutic landscape of several genitourinary malignancies has been revolutionized by the development of immune checkpoint inhibitors (ICIs); however, the utility of immunotherapies in prostate cancer has been limited, partly due to the immunologically "cold" tumor terrain of prostate cancer. As of today, pembrolizumab is the only immune checkpoint inhibitor approved for the treatment of metastatic castration resistant prostate cancer (mCRPC) in a select group of patients with high microsatellite instability (MSI-H), deficient mismatch repair (dMMR), or high tumor mutational burden (TMB). Looking ahead, several combinatorial approaches with ICIs involving radioligands, radiotherapy, PARP inhibitors, interleukin inhibitors, and cancer vaccines are exploring a potential synergistic effe

SUBMITTER: Lanka SM 

PROVIDER: S-EPMC10137248 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature